Çocuk Sağlığı ve Hastalıkları Dergisi 2005 , Vol 48 , Num 2
Inhaled iloprost to treat neonatal pulmonary hypertension
Ercan Sivaslı1, Murat Yurdakök2, Tevfik Karagöz1, Ayşe Korkmaz3 Şule Yiğit2, Gülsevin Tekinalp2
1Hacettepe Üniversitesi Tıp Fakültesi Pediatri Uzmanı
2Hacettepe Üniversitesi Tıp Fakültesi Pediatri Profesörü
3 Hacettepe Üniversitesi Tıp Fakültesi Pediatri Yardımcı Doçenti
Sivaslı E, Yurdakök M, Karagöz T, Korkmaz A, Yigit S, Tekinalp G. (Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey). Inhaled iloprost to treat neonatal pulmonary hypertension. Çocuk Sağlığı ve Hastalıkları Dergisi 2005; 48: 142-146.

Persistent pulmonary hypertension (PPH), which has high morbidity and mortality due to the difficulty in treatment, is an important disease of the newborn period. A wide range of vasodilator drugs have been used in the treatment as the primary event is pulmonary vasoconstriction in the pathogenesis. When iloprost is administered via aerosolization to patients with pulmonary hypertension, it induces selective vasodilatation on pulmonary vessels. Records of nine newborn infants diagnosed as PPH and treated with inhaled iloprost treatment were resrospectively evaluated. Mean duration of inhaled iloprost treatment was 4.7 ± 4.1 days (1-15 days). No patient receiving inhaled iloprost had a decrease in systemic blood pressure or oxygen saturation. No respiratory difficulty was observed during administration. As inhaled nitric oxide cannot be applied in our country, the use of iloprost may be preferred instead in the effective treatment of PPH in the newborn period owing to its low systemic side effects, high tolerability and reliability. Anahtar Kelimeler : yenidoğan, pulmoner hipertansiyon, inhale iloprost, newborn, pulmonary hypertension, inhaled iloprost

Copyright © 2016 cshd.org.tr